All News
Filter News
Found 199 articles
-
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 25, 2021
8/25/2021
OptiNose, Inc., a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose.
-
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
8/11/2021
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2021, and provided operational updates.
-
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
7/30/2021
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it has successfully completed recruitment in the first of two pivotal clinical trials to evaluate the safety and efficacy of XHANCE® (fluticasone propionate) nasal spray as a treatment for patients with chronic sinusitis (CS).
-
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
7/28/2021
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced preliminary XHANCE® net product revenue of $18.4 million for the three months ended June 30, 2021.
-
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
6/24/2021
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced Dr. Per Djupesland received the European Inventor Award 2021 in the Industry category from the European Patent Office for his invention of the technology that serves as a basis for the Optinose Exhalation Delivery System.
-
Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
6/2/2021
Evidenced-based expert algorithm separates EDS-FLU, marketed as XHANCE®, from standard intranasal steroid sprays, recommending it for patients with nasal polyps whose symptoms persist after using standard intranasal steroid sprays
-
Optinose to Present at the Jefferies Virtual Healthcare Conference
6/1/2021
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET.
-
Nasal Polyps Treatment Market: Pharmacological therapies segment dominated the global market
5/14/2021
Transparency Market Research has published a new report on the nasal polyps treatment market for the forecast period of 2019 - 2027.
-
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
5/11/2021
Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Leanne Kelly as its Chief Financial Officer
-
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
5/5/2021
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time
-
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
4/28/2021
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021
-
New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day
4/27/2021
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced results of a new nationwide survey on chronic nasal congestion, its impact on daily activities, and awareness of nasal polyps as a possible cause.
-
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
4/12/2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the hiring of Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan
-
Optinose to Present at the Needham Virtual Healthcare Conference
4/12/2021
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
3/9/2021
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)
-
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
3/3/2021
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects XHANCE net revenue for 2021 to be at least $80 million
-
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
2/17/2021
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41 st Annual Health Care Conference on March 4, 2021
-
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/25/2021
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 15,000 shares of its common stock to one new employee as an inducement material for accepting employment with OptiNose
-
Optinose Announced Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/21/2020
Opti N ose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 35,000 shares of its common stock to two new employees as an inducement material to them accepting employment with OptiNose. The stock option awards were approved by the Compensation Committee of the
-
Optinose Announces Changes to Board of Directors - Dec 01, 2020
12/1/2020
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced its Board of Directors has named Tomas J. Heyman as a new director.